Aller au menu Aller au contenu Aller à la recherche
  • Français
  • English
  • Français
  • English

Fiche de : MAURIZI Lionel

Département :
Nanosciences


Fonction : CR CNRS

Localisation :

C408A

Tél. : +333 80 39 61 71
E-mail : lionel.maurizi@u-bourgogne.fr

Educations and experiences

Researchgate profile

With a chemical engineering background I started in 2010 a PhD in physical-chemistry on the syntheses and characterizations of nanoparticles for biomedical applications. While going deeper into my nanoparticles skills I learned new knowledge on toxicities and biological behaviors of nanohybrids made for medical purposes.

During my postdoctoral experiences from 2011 to 2016, in particular at EPFL, I continued working on synthesis and characterizations methods “GMP-like" for nanomaterials in order to answer pharmaceutical and medical requirements. I also focused my research on the study and the understanding of the role of nanoobjects physico-chemistry on the living world especially their interactions with protein from biological media: the “Protein Corona

This thematic is driving my actual research at ICB Laboratory (Nanosciences Department).

More details

2007-2010: After a chemical engineering diploma from the University of Technology of Compiegne (UTC), I started a PhD in physical chemistry at the ICB Laboratory on the Elaboration of functionalized nanoparticles: applications as MRI contrast agent. My research was focused on the syntheses of magnetic nanparticles via soft chemistry or hydrothermal and continuous methods with an accurate control of the physicochemical properties and in depth characterizations. Nanoparticles' surfaces were also modified and functionalized for a better biocompatibility, less toxicity and targeting behviors in order to be used as a Magnetic Resonance Imaging (MRI) contrast agent.

2011-2015: I worked for 4 years in Pr. H. Hofmann's team at the Ecole Polytechnique Fédérale de Lausanne (EPFL) on a FP7 European project (Nanodiara) on the development of novel nanotechnology based diagnostic and therapeutic systems for arthritic diseases. My research was centered on one part on the reproducibility and scale-up of the syntheses and methods to face biomedical challenges. On another part, I studied the interactions between nanoparticles and proteins in order to better understand their biological behaviors. This scientific area is commonly called: the “Protein Corona“.

2015-2016: After these projects, I continued my research at Dublin City University (Pr. Dermot Brougham) on a FP7 European project (UNION). Then at Basel University (Pr. Cornelia Palivan) I worked on a Swiss project NCCR (National Centres of Competence in Research). These two projects were focused on the development of physicochemical solutions for biomedical applications such as  “nano-flowers" or “nano-vesicles".

Since the end of 2016: I got a CNRS Researcher (CR) permanent position at the Nanosciences Department of the ICB laboratory to continue working on my thematic focused on  the development of nanomedical solutions and on the understanding of their biological behaviors.

Main fields of expertise

  • Control of physico-chemistry of nanomaterials

More details

Synthesis of inorganic nanoparticles such as iron oxide (SPIONs), titanate nanotubes (TiONTs), gold or polymeric vesicles (polymersomes).

Control of the size, the oxidation state, the composition and the morphology of nanoparticles.

Development of reproducible and up-scalable methods for nanomaterials.

  • “GMP-like" surface modification of nanomaterials for biomedical purposes

More details

  • Surface modification of nanoparticles for better biocompatibility (polymer, core/shell structures, organic molecules…).

    Functionalization of nanohybrids with targeting molecules for bimodal detections.

    Reproducible methods compatible with in vitro and in vivo applications especially pharmacokinetic studies.

  • Biological interactions of nanomaterials

More details

Studies of biological behaviors of nanoparticles such as cytotoxicity, cellular interactions and biodistribution.

Development of innovative analysis methods of nanohybrids for biological studies.

Understanding of the role of physico-chemistry in the interactions nanoparticles / proteins: Protein Corona.

Main projects in progress

2021-2026: ANR JC/JC Nanoblorona
Nanoparticles in blood: understanding and controlling protein corona for optimized nanomedicine

Role during the project: Project leader.

The main goal of this project is to understand, control and optimize protein corona on NPs to avoid suffering random protein adsorption affecting the biomedical efficiencies of engineered NPs circulating in blood.

This project proposes a comprehensive study focused on NPs/proteins interactions in blood circulation in order to control their biological response.

2021-2024: ANR UFO
Up-conversion ferroelectric nanocrystal for optical sensing for electric potential in biological systems

Role during the project: Member of WP3 (Project leader F. Treussart ENS Paris-Saclay)

Developing an optical nanosensor of extracellular potential in biological environment that transduces cell-related electrical changes (e.g. EAP in the case of neurons) into photoluminescence (PL) modifications relying on a mechanism never explored.

2020-2022: Collaborative Research Project France-Stanford
Monitoring therapeutic cell treatments using novel nanoprobes.
Role during the project: Project leader.

Tissue regeneration through transplantation of therapeutic stem cells has the potential to revolutionize modern medicine by migrating and differentiating to integrate into their biological environment. We propose to test innovative nanomaterials, which possess unique properties that make them detectable simultaneously by two medical imaging techniques to label stem cells and monitor the efficacy of therapeutic stem cells. Visits and collaborations with Stanford Medicine: Pr. Daldrup-Link Lab.

2019-2022: Regional project on the studies and understanding of proteins interactions with NPs' surfaces (Inititation of a new research team ANER: Nanoprot” n° 2019-Y-10648)

Role during the project: Project leader.

This project focuses on the in depth study and understanding of the parameters influencing the adsorption of proteins on the surface of nanoparticles of various parameters (surface chemistry, charges, shape, size…). The idea is also to understand how this protein corona influences chemical, colloidal and biological behaviors of nanoparticles. This project is mainly done by the PhD student Célia Marets and in collaborations with University of Geneva.


Main projects completed

2019-2020: Equipex Imappi
In vivo studies linking the interactions between proteins and nanoparticles and their biodistribution for an optimized development of nanomedicine (ANR-10-EQPX-05 IMAPPI 2020-IMAPPI-1)

Role during the project: Project leader.

2016: Swiss project NCCR (National Centers of Competence in Research)
Molecular Systems Engineering on the development of innovative molecular systems approaching the complexity of a cell.
Role during the project: Member of the project

More details

Description du projet:

Project description:

This NCCR project was pooling multidisciplinary areas from the physics and chemistry to the biology, the biostatistics and the computer sciences.

The main objctive of the “Molecular Systems Engineering" project was to create complex molecular layouts to mimic cellular reactions. Such systems can be use as organic molecules (enzymes for example) industrial productions or to control cellular systemps for applications in health.

The Molecular Systems Egineering project was divided into 4 Work Packages (more details).

  • WP 1: Molecular modules
  • WP 2: Molecular systems
  • WP 3: Molecular factories
  • WP 4: Cellular systems

Role during the project:

As a scientist in the WP 2 of University of Basel, my role was to develop stimulo-sensitive membranes made from the assembly of polymeric vesicles (polymersomes) and inorganic nanoparticles functionalized with DNA. These membranes shoul induce cascade reactions between the vesicles and catalyzed by the chosen nanoparticles (more details).

2011-2014: FP7 European project (Nanodiara)
Development of nanotechnological tools for the detection and the therapy of arthrtic diseases.

Role during the project: Co-project leader of WP1

More details

Project description:

Although treatment of rheumatoid arthritis (RA) has improved in the last years, there is still no disease modifying treatment for osteoarthritis (OA). For treatments to be effective it is considered extremely important to detect and treat these diseases early and then be able to monitor treatment efficacy early on (within weeks or months) after its initiation rather than waiting up to a year for RA and 18 months for OA. RA is a chronic inflammatory joint disease that involves acute and chronic synovial (joint lining) inflammation causing the erosive destruction of articular cartilages, ligaments and subchondral bone. It develops in about 1% of the population. OA, currently the main cause of disability among the middle age and elderly populations, is a degenerative arthritis involving much less synovial inflammation in most patients, with a prevalence of about 12% of the population.

The main objective of the NanoDiaRA project is the development of nanotechnology-based diagnostic tools for easy and early detection of disease onset, progression and responses to therapy RA and OA via specific targeting of inflammatory areas and imaging with Magnetic Resonance Imaging (MRI).  New blood and urine nanotechnology-based diagnostic biomarker assays was also developed to be a very sensitive, easy to use and affordable immunoassay benchtop analytical systems for widespread clinical use. In view of the development of this targeted nanoparticle-based technology there are also opportunities to use this tissue-targeted approach for locally controlled drug release (e.g. in joints alone/intra-articular). This way of improving drug delivery to minimize possible side effects is a long term future approach which will be examined for its feasibility during the term of the project. The overall project follows a personalized medicine approach and is driven by the prominent unmet clinical needs outlined above.

Nanodiara pooled 15 European partners from academic and industrial fields:

  1. Coordinator: Europäische Akademie GmbH, Bad Neuenahr-Ahrweiler, Germany
  2. Scientific coordinator: MatSearch Consulting Hofmann, Lausanne, Switzerland
  3. Charité Universitätsmedizin (team 1 et team 2), Berlin, Germany
  4. EPFL, Lausanne, Switzerland
  5. University of Lund, Sweden
  6. Merck® Serono, Darmastadt, Germany
  7. AnaMar AB, Lund, Sweden
  8. Arrayon Biotechnology, Neuchâtel, Switzerland
  9. CSEM SA, Neuchâtel, Switzerland
  10. Merck Estapor/OEM-Diagnostic/Merck-Millipore, Pithiviers, France
  11. PMU Salzburg, Austria
  12. University of Fribourg, Switzerland
  13. University of Geneva, Switzerland
  14. University of Nijmegen, Netherlands
  15. University of Tartu, Estonia

The NanoDiaRA project is divided into five research work packages and four supporting work packages. While the research packages deal with fundamental research, the latter are particularly addressing dissemination, publication and valorization of the research outcome, investigation of the ethical issues, training of young investigators and the administration of the project.

WP 1: Particle coating and functionalisation and novel equipment for coating and separation
WP 2: Inflammation and tissue damage detection by cell and tissue tracking and molecular MRI based imaging
WP 3a: New Biomarker/ligand and antibody detection and development: targets, antibodies and peptides
WP 3b: New Biomarker/ligand and antibody detection and development: Clinical relevance
WP 4: Development of bioassays
WP 7: Toxicity

WP 5: Scientific Coordination and Data Management
WP 6: Ethical, Legal, and Social Aspects, Technology Assessment (ELSI)
WP 8: Dissemination of Results and Foreground, Communication, Education & Training
WP 9: Management

Role during the project:

As a scientist and WP leader at EPFL, my role was pivotal and consisted in bringing nanotechnological solutions to our biological, industrial and medical partners. As main responsibles of the WP 1, we worked in close collaborations with all the scientific WP to develop specific nanoparticles for arthritic pathologies with industrial requirements such as biocompatibility and upscalable methods to have enough quantity of materials for pharmacokinetic studies. We also studied in depth the biological behaviors of our nanohybrids (toxicity, internalization, biodistribution or Protein Corona).



Summary of publications

36 articles in peer-reviewed journals

4 international conferences proceedings

4 Book chapters

ORCID number: 0000-0002-6346-7623
Google scholar ; Publons: E-3606-2016 and Scopus: 40262179400

Guest Editor of Special Issues

2020-2021 in Applied Sciences [IF=2.679] “Applications of nanoparticles in Pharmaceuticals


Most significant recent publications

    1. Protein Corona Composition of Superparamagnetic Iron Oxide Nanoparticles with Various Physico-Chemical Properties and Coatings, Scientific Reports, 4, 5020, 2014 (DOI:10.1038/srep05020)
    2. Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats, Nanoscale, 6, (19), 11439-11450, 2014 (DOI:10.1039/C4NR02793K)
    3. Influence of surface charge and polymer coating on internalization and biodistribution of PEG-modified iron oxide nanoparticles, J. Biomed. Nanotech., 11, (1), 126-136, 2015 (DOI:10.1166/jbn.2015.1996)
    4. Significance of surface charge and shell material of Super-paramagnetic Iron Oxide Nanoparticles (SPIONs) based core/shell nanoparticles on the composition of the protein corona, Biomater. Sci., 3, (2), 265-278, 2015 (DOI:10.1039/C4BM00264D)
    5. Beyond unpredictability: the importance of reproducibility in understanding the protein corona of nanoparticles, Bioconj. Chem., 29, (10), 3385-3393, 2018 (DOI:10.1021/acs.bioconjchem.8b00554)
    6. Innovative Magnetic Nanoparticles for PET/MRI Bimodal Imaging, ACS Omega, 4, (2), 2637-2648, 2019 (DOI:10.1021/acsomega.8b03283)
    7. Anti-Platelet effect Induced by Iron Oxide Nanoparticles: Correlation with Conformational Change in Fibrinogen, Small, 17, (1), 2004945, 2021 (DOI:10.1002/smll.202004945)

Publications list and Book Chapters details

4 Books chapters

Nanoparticles in the Lung:
Environmental Exposure and Drug Delivery
Edited by Akira Tsuda and Peter Gehr

Section VI:Special Issues
Chapter 16: Physicochemical, Colloidal, and Transport Properties
(pages 251-266)

Heinrich Hofmann, Lionel Maurizi, Marie-Gabrielle Beuzelin, Usawadee Sakulkhu and Vianney Bernau

December 19, 2014 by CRC Press – 403 Pages
ISBN 9781439892794 – CAT# K14165

Unraveling the Safety Profile of Nanoscale Particles and Materials –
From Biomedical to Environmental Applications
Edited by Andreia C. Gomes and Marisa P. Sarria

Chapter 2
Toxicological Risk Assessment of Emerging Nanomaterials: Cytotoxicity, Cellular Uptake, Effects on Biogenesis and Cell Organelle Activity, Acute Toxicity and Biodistribution of Oxide Nanoparticles
(pages 17-36)

Lionel Maurizi, Anne-Laure Papa, Julien Boudon, Sruthi Sudhakaran, Benoit Pruvost, David Vandroux, Johanna Chluba, Gerard Lizard and Nadine Millot

March, 2018 by InTech – 172 Pages
ISBN 9789535139409

Computational Techniques for Analytical Chemistry and Bioanalysis
Edited by Philippe B. Wilson and Martin Grootveld

Chapter 8
Solid State Chemistry: Computational Chemical Analysis for Materials Science
(pages 287-334)

Estelina Lora da Silva, Sandra Galmarini, Lionel Maurizi, Mario Jorge Cesar dos Santos, Tao Yang, David J. Cooke and Marco Molinari

2021 by RSC – 365 Pages
ISBN 978-1-78801-461-8

New Trends in Macromolecular and Supramolecular Chemistry for Biological Applivations
Edited by Marc J.M. Abadie, Mariane Pinteala, Alexandru Rotaru

Chapter 8
Development of Novel Versatile Theranostic Platforms Based on Titanate Nanotubes: Towards safe Nanocarriers for Biomedical Applications
(pages 151-178)

Julien Boudon, Fadoua Sallem, Alexis Loiseau, Lionel Maurizi, Anne-Laure Papa and Nadine Millot

2021 by Springer – 371 Pages
ISBN 978-3-030-57456-7

Communications

51 international and national conferences including:

7 invited talks with international collaborators

Supervisions

  • 4 PhD students (1 in progress)
  • 10 Master theses (1 in progress)
  • 21 students from Bachelor to Master 2 during semesters projects or short internships

Teaching

36 hours per year on supervised project: Fifth year of engineering school: ESIREM (École supérieure d'ingénieurs de recherche en matériaux et en infotronique)
10 hours per year of Analyses project from the Master CAC
4-8 hours per year of supervision of internship of Fourth year engineering students from ESIREM

Organizations of conferences  and general public meetings

Since 2018: Principal investigator of the event “a Class / a Researcher" where pupils meet researchers during visits of researchers to their schools and visits of pupils in the laboratory.

June 2018: Organizer of the ANF NanoMed 2018 (Summer school on Nanomedicine in 2018)

statut_ub:
batiment:
equipe_1:
OCS
fonction_equipe_1:
Agent(e) de service
mots_cles:
adresse:
onglets:
{tab=Carrière} # {tab=Projets} # {tab=Publications} # {tab=Communications} # {tab=Enseignements} # {tab=Administration} # {/tabs}
telephone:
+333 80 39 61 71
e-mail:
lionel.maurizi@u-bourgogne.fr
site_web:
departement:
a:1:{i:0;s:12:"Nanosciences";}
fonction:
CR CNRS
localisation:
C408A
texte_onglets:
carriere:
projets:
communications:
publications:
enseignements:
administration:
kc_data:
a:8:{i:0;s:0:"";s:4:"mode";s:2:"kc";s:3:"css";s:115:"#publications ul { margin-left: 3em; margin-right: 3em; list-style-type: disc; }";s:9:"max_width";s:0:"";s:7:"classes";s:0:"";s:9:"thumbnail";s:0:"";s:9:"collapsed";s:0:"";s:9:"optimized";s:0:"";}
switch:
0
kc_raw_content:
[kc_row use_container="yes" _id="295443"][kc_column width="12/12" video_mute="no" _id="747594"][kc_tabs speed="450" pagination="yes" active_section="1" _id="481035"][kc_tab title="Career" _id="853765"][kc_column_text _id="220258"]

Educations and experiences

[/kc_column_text][kc_spacing height="20" _id="302233"][kc_column_text _id="706591"]

Researchgate profile

With a chemical engineering background I started in 2010 a PhD in physical-chemistry on the syntheses and characterizations of nanoparticles for biomedical applications. While going deeper into my nanoparticles skills I learned new knowledge on toxicities and biological behaviors of nanohybrids made for medical purposes.

During my postdoctoral experiences from 2011 to 2016, in particular at EPFL, I continued working on synthesis and characterizations methods "GMP-like" for nanomaterials in order to answer pharmaceutical and medical requirements. I also focused my research on the study and the understanding of the role of nanoobjects physico-chemistry on the living world especially their interactions with protein from biological media: the "Protein Corona"

This thematic is driving my actual research at ICB Laboratory (Nanosciences Department).

[/kc_column_text][kc_accordion _id="182255" close_all="yes"][kc_accordion_tab title="More details" _id="486679"][kc_column_text _id="787656"]

2007-2010: After a chemical engineering diploma from the University of Technology of Compiegne (UTC), I started a PhD in physical chemistry at the ICB Laboratory on the Elaboration of functionalized nanoparticles: applications as MRI contrast agent. My research was focused on the syntheses of magnetic nanparticles via soft chemistry or hydrothermal and continuous methods with an accurate control of the physicochemical properties and in depth characterizations. Nanoparticles' surfaces were also modified and functionalized for a better biocompatibility, less toxicity and targeting behviors in order to be used as a Magnetic Resonance Imaging (MRI) contrast agent.

2011-2015: I worked for 4 years in Pr. H. Hofmann's team at the Ecole Polytechnique Fédérale de Lausanne (EPFL) on a FP7 European project (Nanodiara) on the development of novel nanotechnology based diagnostic and therapeutic systems for arthritic diseases. My research was centered on one part on the reproducibility and scale-up of the syntheses and methods to face biomedical challenges. On another part, I studied the interactions between nanoparticles and proteins in order to better understand their biological behaviors. This scientific area is commonly called: the "Protein Corona".

2015-2016: After these projects, I continued my research at Dublin City University (Pr. Dermot Brougham) on a FP7 European project (UNION). Then at Basel University (Pr. Cornelia Palivan) I worked on a Swiss project NCCR (National Centres of Competence in Research). These two projects were focused on the development of physicochemical solutions for biomedical applications such as  "nano-flowers" or "nano-vesicles".

Since the end of 2016: I got a CNRS Researcher (CR) permanent position at the Nanosciences Department of the ICB laboratory to continue working on my thematic focused on  the development of nanomedical solutions and on the understanding of their biological behaviors.

[/kc_column_text][/kc_accordion_tab][/kc_accordion][kc_spacing height="10px" _id="346606"][kc_column_text _id="412159"]

Main fields of expertise

[/kc_column_text][kc_spacing height="20" _id="914005"][kc_column_text _id="929411"]
  • Control of physico-chemistry of nanomaterials
[/kc_column_text][kc_accordion _id="453620" close_all="yes"][kc_accordion_tab title="More details" _id="642604"][kc_column_text _id="419249"]

Synthesis of inorganic nanoparticles such as iron oxide (SPIONs), titanate nanotubes (TiONTs), gold or polymeric vesicles (polymersomes).

Control of the size, the oxidation state, the composition and the morphology of nanoparticles.

Development of reproducible and up-scalable methods for nanomaterials.

[/kc_column_text][/kc_accordion_tab][/kc_accordion][kc_column_text _id="525335"]

  • "GMP-like" surface modification of nanomaterials for biomedical purposes

[/kc_column_text][kc_accordion _id="532148" close_all="yes"][kc_accordion_tab title="More details" _id="942246"][kc_column_text _id="31254"]

  • Surface modification of nanoparticles for better biocompatibility (polymer, core/shell structures, organic molecules…).

    Functionalization of nanohybrids with targeting molecules for bimodal detections.

    Reproducible methods compatible with in vitro and in vivo applications especially pharmacokinetic studies.

[/kc_column_text][/kc_accordion_tab][/kc_accordion][kc_column_text _id="403036"]

  • Biological interactions of nanomaterials

[/kc_column_text][kc_accordion _id="309899" close_all="yes"][kc_accordion_tab title="More details" _id="26620"][kc_column_text _id="167682"]

Studies of biological behaviors of nanoparticles such as cytotoxicity, cellular interactions and biodistribution.

Development of innovative analysis methods of nanohybrids for biological studies.

Understanding of the role of physico-chemistry in the interactions nanoparticles / proteins: Protein Corona.

[/kc_column_text][/kc_accordion_tab][/kc_accordion][/kc_tab][kc_tab title="Projects" _id="76467"][kc_column_text _id="900139"]

Main projects in progress

[/kc_column_text][kc_spacing height="20px" _id="63706"][kc_column_text _id="605962"]

2021-2026: ANR JC/JC Nanoblorona
Nanoparticles in blood: understanding and controlling protein corona for optimized nanomedicine

Role during the project: Project leader.

The main goal of this project is to understand, control and optimize protein corona on NPs to avoid suffering random protein adsorption affecting the biomedical efficiencies of engineered NPs circulating in blood.

This project proposes a comprehensive study focused on NPs/proteins interactions in blood circulation in order to control their biological response.

[/kc_column_text][kc_spacing height="10px" _id="661304"][kc_column_text _id="171430"]

2021-2024: ANR UFO
Up-conversion ferroelectric nanocrystal for optical sensing for electric potential in biological systems

Role during the project: Member of WP3 (Project leader F. Treussart ENS Paris-Saclay)

Developing an optical nanosensor of extracellular potential in biological environment that transduces cell-related electrical changes (e.g. EAP in the case of neurons) into photoluminescence (PL) modifications relying on a mechanism never explored.

[/kc_column_text][kc_spacing height="10px" _id="566291"][kc_column_text _id="298148"]

2020-2022: Collaborative Research Project France-Stanford
Monitoring therapeutic cell treatments using novel nanoprobes.
Role during the project: Project leader.

Tissue regeneration through transplantation of therapeutic stem cells has the potential to revolutionize modern medicine by migrating and differentiating to integrate into their biological environment. We propose to test innovative nanomaterials, which possess unique properties that make them detectable simultaneously by two medical imaging techniques to label stem cells and monitor the efficacy of therapeutic stem cells. Visits and collaborations with Stanford Medicine: Pr. Daldrup-Link Lab.

[/kc_column_text][kc_spacing height="10px" _id="498065"][kc_column_text _id="666328"]

2019-2022: Regional project on the studies and understanding of proteins interactions with NPs' surfaces (Inititation of a new research team ANER: Nanoprot” n° 2019-Y-10648)

Role during the project: Project leader.

This project focuses on the in depth study and understanding of the parameters influencing the adsorption of proteins on the surface of nanoparticles of various parameters (surface chemistry, charges, shape, size...). The idea is also to understand how this protein corona influences chemical, colloidal and biological behaviors of nanoparticles. This project is mainly done by the PhD student Célia Marets and in collaborations with University of Geneva.

[/kc_column_text][kc_spacing height="10px" _id="952945"][kc_column_text _id="406219"]
[/kc_column_text][kc_spacing height="10px" _id="519689"][kc_column_text _id="523410"]

Main projects completed

[/kc_column_text][kc_spacing height="20px" _id="702449"][kc_column_text _id="78185"]

2019-2020: Equipex Imappi
In vivo studies linking the interactions between proteins and nanoparticles and their biodistribution for an optimized development of nanomedicine (ANR-10-EQPX-05 IMAPPI 2020-IMAPPI-1)

Role during the project: Project leader.

[/kc_column_text][kc_spacing height="10px" _id="761567"][kc_column_text _id="2139"]

2016: Swiss project NCCR (National Centers of Competence in Research)
Molecular Systems Engineering on the development of innovative molecular systems approaching the complexity of a cell.
Role during the project: Member of the project

[/kc_column_text][kc_accordion _id="699407" close_all="yes"][kc_accordion_tab title="More details" _id="727853"][kc_column_text _id="122321"]

Description du projet:

Project description:

This NCCR project was pooling multidisciplinary areas from the physics and chemistry to the biology, the biostatistics and the computer sciences.

The main objctive of the "Molecular Systems Engineering" project was to create complex molecular layouts to mimic cellular reactions. Such systems can be use as organic molecules (enzymes for example) industrial productions or to control cellular systemps for applications in health.

[/kc_column_text][kc_column_text _id="114900"]

The NCCR project pooled 9 Swiss partners from academic and industrail fields:

  1. ETH Zürich
  2. EPFL
  3. Friedrich Miescher Institute
  4. IBM Research Zurich
  5. Paul Scherrer Institute
  6. University of Basel
  7. University of Bern
  8. University of Geneva
  9. University of Zürich
[/kc_column_text][kc_column_text _id="186877"]

The Molecular Systems Egineering project was divided into 4 Work Packages (more details).

  • WP 1: Molecular modules
  • WP 2: Molecular systems
  • WP 3: Molecular factories
  • WP 4: Cellular systems

[/kc_column_text][kc_column_text _id="514637"]

Role during the project:

As a scientist in the WP 2 of University of Basel, my role was to develop stimulo-sensitive membranes made from the assembly of polymeric vesicles (polymersomes) and inorganic nanoparticles functionalized with DNA. These membranes shoul induce cascade reactions between the vesicles and catalyzed by the chosen nanoparticles (more details).

[/kc_column_text][/kc_accordion_tab][/kc_accordion][kc_column_text _id="965003"]

2011-2014: FP7 European project (Nanodiara)
Development of nanotechnological tools for the detection and the therapy of arthrtic diseases.

Role during the project: Co-project leader of WP1

[/kc_column_text][kc_accordion _id="527961" close_all="yes"][kc_accordion_tab title="More details" _id="869179"][kc_column_text _id="390479"]

Project description:

Although treatment of rheumatoid arthritis (RA) has improved in the last years, there is still no disease modifying treatment for osteoarthritis (OA). For treatments to be effective it is considered extremely important to detect and treat these diseases early and then be able to monitor treatment efficacy early on (within weeks or months) after its initiation rather than waiting up to a year for RA and 18 months for OA. RA is a chronic inflammatory joint disease that involves acute and chronic synovial (joint lining) inflammation causing the erosive destruction of articular cartilages, ligaments and subchondral bone. It develops in about 1% of the population. OA, currently the main cause of disability among the middle age and elderly populations, is a degenerative arthritis involving much less synovial inflammation in most patients, with a prevalence of about 12% of the population.

[/kc_column_text][kc_column_text _id="970339"]

The main objective of the NanoDiaRA project is the development of nanotechnology-based diagnostic tools for easy and early detection of disease onset, progression and responses to therapy RA and OA via specific targeting of inflammatory areas and imaging with Magnetic Resonance Imaging (MRI).  New blood and urine nanotechnology-based diagnostic biomarker assays was also developed to be a very sensitive, easy to use and affordable immunoassay benchtop analytical systems for widespread clinical use. In view of the development of this targeted nanoparticle-based technology there are also opportunities to use this tissue-targeted approach for locally controlled drug release (e.g. in joints alone/intra-articular). This way of improving drug delivery to minimize possible side effects is a long term future approach which will be examined for its feasibility during the term of the project. The overall project follows a personalized medicine approach and is driven by the prominent unmet clinical needs outlined above.

[/kc_column_text][kc_column_text _id="833334"]

Nanodiara pooled 15 European partners from academic and industrial fields:

  1. Coordinator: Europäische Akademie GmbH, Bad Neuenahr-Ahrweiler, Germany
  2. Scientific coordinator: MatSearch Consulting Hofmann, Lausanne, Switzerland
  3. Charité Universitätsmedizin (team 1 et team 2), Berlin, Germany
  4. EPFL, Lausanne, Switzerland
  5. University of Lund, Sweden
  6. Merck® Serono, Darmastadt, Germany
  7. AnaMar AB, Lund, Sweden
  8. Arrayon Biotechnology, Neuchâtel, Switzerland
  9. CSEM SA, Neuchâtel, Switzerland
  10. Merck Estapor/OEM-Diagnostic/Merck-Millipore, Pithiviers, France
  11. PMU Salzburg, Austria
  12. University of Fribourg, Switzerland
  13. University of Geneva, Switzerland
  14. University of Nijmegen, Netherlands
  15. University of Tartu, Estonia

[/kc_column_text][kc_column_text _id="414228"]

The NanoDiaRA project is divided into five research work packages and four supporting work packages. While the research packages deal with fundamental research, the latter are particularly addressing dissemination, publication and valorization of the research outcome, investigation of the ethical issues, training of young investigators and the administration of the project.

WP 1: Particle coating and functionalisation and novel equipment for coating and separation
WP 2: Inflammation and tissue damage detection by cell and tissue tracking and molecular MRI based imaging
WP 3a: New Biomarker/ligand and antibody detection and development: targets, antibodies and peptides
WP 3b: New Biomarker/ligand and antibody detection and development: Clinical relevance
WP 4: Development of bioassays
WP 7: Toxicity

WP 5: Scientific Coordination and Data Management
WP 6: Ethical, Legal, and Social Aspects, Technology Assessment (ELSI)
WP 8: Dissemination of Results and Foreground, Communication, Education & Training
WP 9: Management

[/kc_column_text][kc_column_text _id="112240"]

Role during the project:

As a scientist and WP leader at EPFL, my role was pivotal and consisted in bringing nanotechnological solutions to our biological, industrial and medical partners. As main responsibles of the WP 1, we worked in close collaborations with all the scientific WP to develop specific nanoparticles for arthritic pathologies with industrial requirements such as biocompatibility and upscalable methods to have enough quantity of materials for pharmacokinetic studies. We also studied in depth the biological behaviors of our nanohybrids (toxicity, internalization, biodistribution or Protein Corona).

[/kc_column_text][/kc_accordion_tab][/kc_accordion][/kc_tab][kc_tab title="Publications" _id="240445"][kc_column_text _id="137763"]


[/kc_column_text][kc_column_text _id="759812"]
[/kc_column_text][kc_column_text _id="646177"]

[/kc_column_text][kc_spacing height="20px" _id="477328"][kc_column_text _id="306793"]

Summary of publications

[/kc_column_text][kc_spacing height="20px" _id="731312"][kc_column_text _id="651713"]

36 articles in peer-reviewed journals

4 international conferences proceedings

4 Book chapters

ORCID number: 0000-0002-6346-7623
Google scholar ; Publons: E-3606-2016 and Scopus: 40262179400
[/kc_column_text][kc_spacing height="10px" _id="416809"][kc_carousel_images img_size="full" items_number="3" tablet="2" mobile="1" speed="500" pagination="yes" auto_play="yes" delay="8" alt_text="__empty__" _id="773446" images="20316,20317,21070" onclick="custom_link" custom_links="aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAzOS9DNEJNMDAyNjREDQpodHRwOi8vZHguZG9pLm9yZy8xMC4xMDAyL3NtbGwuMjAyMDA0OTQ1DQpodHRwczovL2RvaS5vcmcvMTAuMTAzOS9EME5BMDA4NjNK" custom_links_target="_blank"][kc_column_text _id="462406"]
[/kc_column_text][kc_spacing height="20px" _id="477152"][kc_column_text _id="977628"]

Guest Editor of Special Issues

2020-2021 in Applied Sciences [IF=2.679] "Applications of nanoparticles in Pharmaceuticals"

[/kc_column_text][kc_spacing height="20px" _id="666627"][kc_column_text _id="119949"]
[/kc_column_text][kc_column_text _id="584312"]

Most significant recent publications

[/kc_column_text][kc_spacing height="20px" _id="672102"][kc_column_text _id="494600"]
    1. Protein Corona Composition of Superparamagnetic Iron Oxide Nanoparticles with Various Physico-Chemical Properties and Coatings, Scientific Reports, 4, 5020, 2014 (DOI:10.1038/srep05020)
    2. Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats, Nanoscale, 6, (19), 11439-11450, 2014 (DOI:10.1039/C4NR02793K)
    3. Influence of surface charge and polymer coating on internalization and biodistribution of PEG-modified iron oxide nanoparticles, J. Biomed. Nanotech., 11, (1), 126-136, 2015 (DOI:10.1166/jbn.2015.1996)
    4. Significance of surface charge and shell material of Super-paramagnetic Iron Oxide Nanoparticles (SPIONs) based core/shell nanoparticles on the composition of the protein corona, Biomater. Sci., 3, (2), 265-278, 2015 (DOI:10.1039/C4BM00264D)
    5. Beyond unpredictability: the importance of reproducibility in understanding the protein corona of nanoparticles, Bioconj. Chem., 29, (10), 3385-3393, 2018 (DOI:10.1021/acs.bioconjchem.8b00554)
    6. Innovative Magnetic Nanoparticles for PET/MRI Bimodal Imaging, ACS Omega, 4, (2), 2637-2648, 2019 (DOI:10.1021/acsomega.8b03283)
    7. Anti-Platelet effect Induced by Iron Oxide Nanoparticles: Correlation with Conformational Change in Fibrinogen, Small, 17, (1), 2004945, 2021 (DOI:10.1002/smll.202004945)
[/kc_column_text][kc_spacing height="20px" _id="453864"][kc_column_text _id="740700"]

Publications list and Book Chapters details

[/kc_column_text][kc_spacing height="20px" _id="78263"][kc_accordion _id="463901" close_all="yes"][kc_accordion_tab title="Publications list" _id="271166"][kc_raw_code code="PGlmcmFtZSBzdHlsZT0id2lkdGg6MTAwJTtoZWlnaHQ6NzV2aDsiIHNyYz0iaHR0cHM6Ly9oYWx0b29scy5hcmNoaXZlcy1vdXZlcnRlcy5mci9QdWJsaWMvYWZmaWNoZVJlcXVldGVQdWJsaS5waHA/aWRIYWw9bGlvbmVsLW1hdXJpemkmQ0JfYXV0ZXVyPW91aSZDQl90aXRyZT1vdWkmQ0JfYXJ0aWNsZT1vdWkmbGFuZ3VlPUFuZ2xhaXMmdHJpX2V4cD1hbm5lZV9wdWJsaSZ0cmlfZXhwMj10eXBkb2MmdHJpX2V4cDM9ZGF0ZV9wdWJsaSZvcmRyZV9hZmY9VEEmRmVuPUFmZiZjc3M9Li4vY3NzL1Zpc3VSdWJyaXF1ZUVuY2FkcmUuY3NzIj48L2lmcmFtZT4NCg==" _id="466761"][/kc_accordion_tab][/kc_accordion][kc_accordion _id="404457" close_all="yes"][kc_accordion_tab title="4 Books chapters" _id="193200"][kc_column_text _id="813088"]

Nanoparticles in the Lung:
Environmental Exposure and Drug Delivery
Edited by Akira Tsuda and Peter Gehr

Section VI:Special Issues
Chapter 16: Physicochemical, Colloidal, and Transport Properties
(pages 251-266)

Heinrich Hofmann, Lionel Maurizi, Marie-Gabrielle Beuzelin, Usawadee Sakulkhu and Vianney Bernau

December 19, 2014 by CRC Press - 403 Pages
ISBN 9781439892794 - CAT# K14165

[/kc_column_text][kc_column_text _id="267543"]

Unraveling the Safety Profile of Nanoscale Particles and Materials -
From Biomedical to Environmental Applications
Edited by Andreia C. Gomes and Marisa P. Sarria

Chapter 2
Toxicological Risk Assessment of Emerging Nanomaterials: Cytotoxicity, Cellular Uptake, Effects on Biogenesis and Cell Organelle Activity, Acute Toxicity and Biodistribution of Oxide Nanoparticles
(pages 17-36)

Lionel Maurizi, Anne-Laure Papa, Julien Boudon, Sruthi Sudhakaran, Benoit Pruvost, David Vandroux, Johanna Chluba, Gerard Lizard and Nadine Millot

March, 2018 by InTech - 172 Pages
ISBN 9789535139409

[/kc_column_text][kc_column_text _id="918112"]

Computational Techniques for Analytical Chemistry and Bioanalysis
Edited by Philippe B. Wilson and Martin Grootveld

Chapter 8
Solid State Chemistry: Computational Chemical Analysis for Materials Science
(pages 287-334)

Estelina Lora da Silva, Sandra Galmarini, Lionel Maurizi, Mario Jorge Cesar dos Santos, Tao Yang, David J. Cooke and Marco Molinari

2021 by RSC - 365 Pages
ISBN 978-1-78801-461-8

[/kc_column_text][kc_column_text _id="161204"]

New Trends in Macromolecular and Supramolecular Chemistry for Biological Applivations
Edited by Marc J.M. Abadie, Mariane Pinteala, Alexandru Rotaru

Chapter 8
Development of Novel Versatile Theranostic Platforms Based on Titanate Nanotubes: Towards safe Nanocarriers for Biomedical Applications
(pages 151-178)

Julien Boudon, Fadoua Sallem, Alexis Loiseau, Lionel Maurizi, Anne-Laure Papa and Nadine Millot

2021 by Springer - 371 Pages
ISBN 978-3-030-57456-7

[/kc_column_text][/kc_accordion_tab][/kc_accordion][/kc_tab][kc_tab title="Communications / Teachings" _id="557667"][kc_column_text _id="712392"]

Communications

[/kc_column_text][kc_spacing height="20px" _id="388921"][kc_column_text _id="981339"]

51 international and national conferences including:

7 invited talks with international collaborators

[/kc_column_text][kc_spacing height="20px" _id="543635"][kc_column_text _id="139475"]

Supervisions

[/kc_column_text][kc_spacing height="20px" _id="830768"][kc_column_text _id="485833"]

  • 4 PhD students (1 in progress)
  • 10 Master theses (1 in progress)
  • 21 students from Bachelor to Master 2 during semesters projects or short internships
[/kc_column_text][kc_spacing height="20px" _id="795246"][kc_column_text _id="87744"]

Teaching

[/kc_column_text][kc_spacing height="20px" _id="380147"][kc_column_text _id="805929"]

36 hours per year on supervised project: Fifth year of engineering school: ESIREM (École supérieure d'ingénieurs de recherche en matériaux et en infotronique)
10 hours per year of Analyses project from the Master CAC
4-8 hours per year of supervision of internship of Fourth year engineering students from ESIREM

[/kc_column_text][kc_spacing height="20px" _id="665909"][kc_column_text _id="159154"]

Organizations of conferences  and general public meetings

[/kc_column_text][kc_spacing height="20px" _id="46662"][kc_column_text _id="143736"]

Since 2018: Principal investigator of the event "a Class / a Researcher" where pupils meet researchers during visits of researchers to their schools and visits of pupils in the laboratory.

June 2018: Organizer of the ANF NanoMed 2018 (Summer school on Nanomedicine in 2018)

[/kc_column_text][/kc_tab][/kc_tabs][/kc_column][/kc_row]

Log In

Create an account